IBEX 35
9.431,30 +3,30 (+0,04%) Euro Stoxx 50
4.160,16 -14,50 (-0,35%) Dólar/Euro
1,0525 -0,0050 (-0,47%) Petróleo Brent
95,33 +0,02 (+0,02%) Oro
1.848,50 -17,60 (-0,94%) Bitcoin EUR
27.001,59 +1.178,44 (+4,56%)
AbbVie Inc. (ABBV)
AbbVie Inc.
1 North Waukegan Road
North Chicago, IL 60064-6400
United States
847 932 7900
https://www.abbvie.com
Sector(es): Healthcare
Sector: Drug Manufacturers—General
Empleados a tiempo completo: 50.000
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Richard A. Gonzalez | Chairman & CEO | 6,95M | N/A | 1954 |
| Mr. Robert A. Michael | Pres & COO | 4M | N/A | 1970 |
| Mr. Scott T. Reents | Exec. VP & CFO | 2,97M | N/A | 1968 |
| Dr. Azita Saleki-Gerhardt Ph.D. | Exec. VP & COO | 2,58M | N/A | 1963 |
| Mr. Jeffrey Ryan Stewart | Exec. VP & Chief Commercial Officer | 2,98M | 2,78M | 1969 |
| Dr. Thomas J. Hudson M.D. | Sr. VP of R&D and Chief Scientific Officer | N/A | N/A | 1962 |
| Ms. Elizabeth Shea | VP of Investor Relations | N/A | N/A | N/A |
| Ms. Tracie Haas | Sr. VP of Corp. Responsibility, Brand & Communications | N/A | N/A | N/A |
| Mr. Timothy J. Richmond | Exec. VP & Chief HR Officer | N/A | N/A | 1966 |
| Dr. Nicholas R. Donoghoe M.D. | Exec. VP and Chief Bus. & Strategy Officer | N/A | N/A | 1981 |
Descripción
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; and California Institute for Biomedical Research (Calibr). The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Gobierno corporativo
El ISS Governance QualityScore de AbbVie Inc., a día 28 de septiembre de 2023, es 8. Las puntuaciones base son Auditoría: 10; Tablero: 4; Derechos de los accionistas: 9; Compensación: 6.
